Next Phase Newsletter

A health-focused vision care company committed to cultivating the eye health start-up ecosystem is looking to invest or partner with companies from seed to revenue stage, investing as early as POC through commercially available products. The firm is interested in technologies from all sectors that are related to eye health (including ocular surface disease, myopia, and glaucoma), or diagnostics or treatments for eye problems caused by other diseases, such as diabetes or neurological diseases. The firm will consider seed through late stage investing and partnerships with companies in the US and abroad.

The firm will consider all companies associated with vision, ophthalmology, and vision care. This includes all sectors, and could range from new therapeutics to treat glaucoma to digital health technologies to improve vision insurance. The firm will also consider technologies treating vision problems that are secondary effects of other indications, such as diabetes.

The firm can lead or co-invest. In addition, the firm will use their network for help with product rollout, if relevant.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in California invests in seed and early-stage digital health and therapeutic companies. The typical investment size for seed investment ranges from $500K to $1M (usually in equity or capped, convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based in the United States. The firm is actively seeking new investment opportunities.

The firm is actively seeking new investment opportunities in the digital health sector and areas of interest include: Precision medicine, digital therapeutics, combination data products, scalability solutions and clinical trial management solutions.

The firm often leads financings and takes a board seat, but prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2009 and is based in Paris, France. The firm currently manages three Biofunds, the newest of which closed in 2020 and focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe and North America, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm founded in 2002 and has offices in San Francisco, CA, and Boston, MA. The firm is investing from its sixth fund, which closed at $350 million in 2018. The firm invests in seed and Series A rounds and has a strong preference for being the first institutional investor in a company. The firm typically reserves a total of $25 million to invest over the life of a portfolio company. The firm invests in the USA and Canada, and typically makes about 5 allocations per year.

The firm is primarily focused on therapeutics, and generally will no longer invest in technologies with a medical device regulatory pathway. The firm prefers to invest in platform technologies that have attained significant preclinical proof of concept data, preferably with published data and evidence that shows reproduction of theory. The firm prefers that platform technologies have potential to bring therapeutics to market in the short-term. The firm will consider therapeutic opportunities in any indication space and is agnostic to modality (i.e. small molecule, large molecule, cell/gene therapy). Additionally, the firm invests in biotech research tools, such as sequencing technologies and discovery platforms.

The firm prefers to work with strong scientific teams. The firm invests only in the USA and Canada and does not consider international opportunities unless the company has a significant US presence. The firm generally does not invest in companies that have previously received investments from an institutional investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The fund is a $350M specialist venture capital fund based in Boston, MA and London, UK. The fund was founded in 2015 with the vision of delivering high-impact therapeutics for age-related dementia. The fund is looking to invest in therapeutics to treat all forms of dementia, including Alzheimer’s Disease (AD), Parkinson’s Disease Dementia (PDD), Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s Disease (HD). The fund will invest in all stages, but prefers to invest in companies with novel therapeutics, and supports the companies through multiple rounds to an exit, investing $15-25M over the life of a company. The fund is willing to invest globally.

The fund is open to all forms of therapeutics and has a focus on five scientific themes: neuroinflammation, proteostasis, synaptic physiology, genomic instability, and platform technologies. However, the fund is always open to new scientific approaches for treatments and is willing to consider all mechanisms of action.

The fund is open to leading, or following, and takes a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.